Nanotechnological approaches for the treatment of placental dysfunction: recent trends and future perspectives

The transitory placenta develops during pregnancy and mediates the blood flow between the mother and the developing baby. Placental dysfunction, including but not limited to placenta accreta spectrum, fetal growth restriction, preeclampsia and gestational trophoblastic disease, arises from abnormal...

Full description

Saved in:
Bibliographic Details
Published inNanomedicine (London, England) Vol. 18; no. 26; p. 1961
Main Authors Zhao, Jian, Zhang, Jungang, Xu, Yan, Dong, Juan, Dong, Qichao, Zhao, Guoqiang, Shi, Ying
Format Journal Article
LanguageEnglish
Published England 01.11.2023
Subjects
Female
Fetal Growth Retardation
Humans
Placenta
Pre-Eclampsia
Pregnancy
placental dysfunction
preeclampsia
fetal growth restriction
targeted therapies
nanomedicines
Online AccessGet more information

Cover

More Information
Summary:The transitory placenta develops during pregnancy and mediates the blood flow between the mother and the developing baby. Placental dysfunction, including but not limited to placenta accreta spectrum, fetal growth restriction, preeclampsia and gestational trophoblastic disease, arises from abnormal placental development and can result in significant adverse maternal and fetal health outcomes. Unfortunately, there is a lack of treatment alternatives for these disorders. Nanocarriers offer versatility, including extended circulation, organ-specific targeting and intracellular transport, finely tuning therapeutic placental interactions. This thorough review explores nanotechnological strategies for addressing placental disorders, encompassing dysfunction insights, potential drug-delivery targets and recent strides in placenta-targeted nanoparticle (NP) therapies, instilling hope for effective placental malfunction treatment.
ISSN:1748-6963
DOI:10.2217/nnm-2023-0194